فهرست:
فصل اول:کلیات تحقیق 1
1-1- مقدمه...................................................................................................................................... 1
1-2- بیان مسئله................................................................................................................................ 2
1-3- اهمیت و ضرورت تحقیق......................................................................................................... 5
1-4- اهداف پژوهش............................................................................................................................ 6
اهداف ویژه....................................................................................................................................... 6
اهداف اختصاصی .............................................................................................................................. 6
1-5- فرضیات.................................................................................................................................. 7
1-6- قلمروی تحقیق............................................................................................................................ 7
1-7- محدودیت های تحقیق........................................................................................................... 7
1-8- تعریف واژه گان......................................................................................................................... 8
فصل دوم: مبانی نظری و پیشینه تحقیق 9
1-2- مقدمه................................................................................................................................... 10
2-2- مبانی نظری تحقیق.................................................................................................................... 10
2-2-1- چاقی.................................................................................................................................. 10
2-2-2- سندرم متابولیک................................................................................................................... 11
2-2-3- مقاومت انسولین............................................................................................................... 12
2-2-4- دیابت ملیتوس(نوع دوم)............................................................................................................ 13
2-2-5- پاتو فیزیولوژی دیابت نوع دو........................................................................................................ 14
2-2-6- بافت چربی........................................................................................................................ 15
2-2-7- متابولیسم بافت چربی............................................................................................................... 15
2-2-8- پروتئینهای مشتق از چربی......................................................................................................... 16
2-2-9- مروری بر دستگاه ایمنی............................................................................................................ 17
2-2-10- نمای کلی دستگاه ایمنی.......................................................................................................... 17
2-2-10- ایمنی ذاتی و ایمنی اکتسابی................................................................................................... 17
2-2-11- سلول های دستگاه ایمنی......................................................................................................... 19
2-2-12-گلبول های سفید............................................................................................................. 19
2-2-13- التهاب............................................................................................................................ 21
2-2-14- عوامل محلول در پاسخ های ایمنی................................................................................... 21
2-2-15- سایتوکاین ها.................................................................................................................. 22
2-2-16- اینترلوکین β1 (β1-IL) ................................................................................................. 24
2-2-17- فاکتور نکروز کننده ی تومور (TNF)................................................................................ 25
2-2-18- چربی (لیپیدها)............................................................................................................... 27
2-2-19- اسیدهای چرب..................................................................................................................... 27
2-2-20- اسیدهای چرب امگا-3..................................................................................................... 28
2-2- 21- EPA،DHA...................................................................................................................... 29
2-2-22- مصرف اسیدهای چرب در رژیم غذایی انسانها.................................................................... 31
2-2-23- چگونگی تاثیر اسیدهای چرب بر دستگاه ایمنی................................................................. 32
2-2-24- پروستوگلاندین 2E و لکوترین 4L....................................................................................34
2-2-25-4L................................................................................................................................... 34
2-2-26-2PGE............................................................................................................................. 34
2-2-27- اثر امگا-3 بر دستگاه ایمنی……………………..…………..…………………………………................... 36
2-2-28- مکانیزم اثر PUFAs بر عوامل التهابی.............................................................................. 36
2-2-29- تاثیر کوتاه مدت مصرف امگا-3 بر دستگاه ایمنی…………………..……….…………………………. 40
2-2-30- فعالیت بدنی و مکمل3n- PUFAs................................................................................... 41
2-2-31- تمرینات فزاینده................................................................................................................... 44
2-3- پیشینه تحقیق....................................................................................................................... 45
فصل سوم: روش شناسی تحقیق 55
3-1- مقدمه................................................................................................................................... 56
3-2- روش تحقیق.......................................................................................................................... 56
3-3- جامعه و نمونه آماری............................................................................................................. 56
3-4- متغییرهای تحقیق................................................................................................................. 57
3-5- مواد مصرفی، ابزارها و روش های جمع آوری داده................................................................... 58
3-6- ابزارهای اندازه گیری............................................................................................................. 59
3-6-1- اندازه گیری حداکثر ضربان قلب(HR max)....................................................................... 59
3-6-2- خون گیری......................................................................................................................... 61
3-6-3- اندازه گیری TNF-α،β 1-IL و انسولین............................................................................... 61
3-6-4- اندازه گیری قد و وزن........................................................................................................ 62
3-7- روش مصرف مکمل................................................................................................................. 62
3-8- روش های آزمایشگاهی........................................................................................................... 62
3-8-1- جمع آوری نمونه خونی....................................................................................................... 62
3-8-2- جداسازی سلول های تک هسته ای خون محیطی (PBMC)................................................................. 63
3-8-3-کشت سلول های PBMC و تحریک آنها به PHA.............................................................................. 63
3-9- روش های آماری.................................................................................................................... 63
فصل چهارم: تجزیه و تحلیل آماری 65
4-1- مقدمه................................................................................................................................... 66
4-2- توصیف داده ها......................................................................................................................66
4-3- آزمون فرضیه ها.................................................................................................................... 67
فرض اول....................................................................................................................................... 66
فرض دوم....................................................................................................................................... 68
فرض سوم...................................................................................................................................... 70
فصل پنجم: بحث و نتیجه گیری 73
بحث و نتیجه گیری..................................................................................................................... 74
5-1- مقدمه...................................................................................................................................74
5-2- خلاصه.................................................................................................................................. 74
نتیجه گیری .................................................................................................................................................................................. 80
5-3-پیشنهادات حاصل از تحقیق....................................................................................................... 81
5-4- پیشنهادات برای تحقیقات آتی:............................................................................................... 81
منابع.................................
منبع:
1-World Health Organization. Definition and diagnosis of diabetes mellitus and intermediatehyperglycemia: WHO/IDF Consultation; 2006
2-World Health Organization and International Diabetes Federation. Diabetes Action Now: Aninitiative of World Health Organization and International Diabetes Federation, 2004
3-Rawal LB, Tapp RJ, Williams ED, Chan C, Yasin S, Oldenburg B. Prevention of Type Diabetes 2 and Its Complications in Developing Countries: A Review. Int J Behav Med. 2011;4:18-28
4-Funnell MM, Brown TL, Childs BP, Haas LB, Hosey GM, Jensen B, et al. National standards for
diabetes self-management education. Diabetes Care. 2008 Jan; 31 Suppl 1: S97-104
5-Thomas GN, Jiang CQ, Taheri S, Xiao ZH, Tomlinson B, Cheung BM, et al. A systematic review of lifestyle modification and glucose intolerance in the prevention of type 2 diabetes. Curr Diabetes Rev. 2010;6:378-8
6-Brunner, E.J. Kivimaki, M. Witte, D.R.Lawlor, D.A. Daveysmith, G. Gooper,J.A. Miller, M.Lowe, G.D. Rummley,A. Casas.J.P. Shah T . Humphries ,S.E. Hingorani, A.D. Maarmot, M.G.Timpson, N.J. and Kumari,M.2008
7-Gomez,J.M. Vila, R. Catalina, P.Soler,J. Badimon,L.and Sahum,M.2008.The markers of inflammation and endothelial dysfunction in correlation with glycated haemoglobin are present in type 2 diabetesmellitus patients but not their relatives.Glycoconj J,25(6),pp.573-579
8-Yaturu, S. Rains, J. and Jain,S.K.2008.Relationship of elevated osteoprotegerin with insulin resistance,CRP,and TNF-lpha levels hn men with type 2diabetes.Cytokine,44(1),pp.168-171.
9-simopoulos, A.P.2002. Omega-3 fatty acids in inflammation and autoimmune diseases.J Am Coll Nutr,21(6),pp.495-505.
10-Martin, R.E. 1998. Docosahexaenoic acid decreases phospholipase A2activity in the neurites/nerve growth cones of PC12 cells.J Neurosci Res,54(6),pp.805-813
11-Kang, J.X. man, S.F. Brown, N.F. Labrecque,P,A.Garg,M.L.and Clandinin, M.T. 1992. Essential fatty acid metabolism in cultured human airway epithelial cell. Biochhm Biophys Acta, 1128(2-3),pp.267-274.
12-Horia, E. and Watkins, B.A. 2007. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and in MDA-MB-231 breast cancer cells.Carcinogenesis,28(4),pp.809-815
13-Saedisomeolia, A. Wood. L.G.Garg,M.L.Gibson, P.G. and Wark, P.A.2009. Anti-inflammatory effects of longchain n-3 PUFA in rhinovirus-infected cultured airway epithelial cells. Br J nutr,101(4),pp.533-540.
14-Marik, P.E. and Varon, J.2009. Omega-3 dietary supplements and the risk of cardovascular events:a systematic riview. Clin Cardiol,32(7),pp,365-372.
15-Freund-Levi,Y. Hjorth,E, Lindberg,C. Cederholm,T.Faxen-Irvin.and Eriksdotter Jonhagen, M.2009.Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimers disease:the OmegaAD study.Dement Gogn Disord,27(5).pp.481-490.
16-Suresh.Y. and Das. U.N. 2003. Longchain polyunsaturated fatty acids and chemically induced diabetes mellitus.effect of omega-3 fatty acids. Nutrition,19(3),pp.213-228.
17-Tsitouras, P.D. Gucciardo,F. Salbe, A.D.Heward,C.Harman, S.M.2008. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6.but does not affect other endocrine axes in healthy older adults.Horm Metab Res,40(3),pp.199-205.
18-Gleeson, M.(2000). Mucosal immune responses and risk of respiratory illness in elite athletes. Exerc Immunol Rev. 6:5-42, 2000.
19-Pan DA, S.Lillioja,A.D Kriketos.skeletal muscle triglyceride levels are inversely related to insolin action.Diabetes..46:983-988.1997
20-Kesaniemi YA, E. Danforth,M.D.Jensen, P.G.Kopelmmn,P.Lefebvre, B.A.Reeder. Dose-response issues concerningphysical activity and healh: an evidence-based symposium.Med Sci Sport Excerc..33:S351-S358.2001
(21لاریجانی،باقر؛فراوانی دیابت نوع دو در ایران در سال 1380 ؛مجله دیابت و لیپید ایران؛دوره 4(شماره 3)؛83-75.بهار 1384
22-Thompson PD,S.F Crouse,B.Goodpaster,D.Kelly,N.Moyan,L.Pescatello.The acute versuthe cronic response to excecise.Med Sci Sport Excerc……..33:S-438-445.2001
23-Calder PC (2005) Polyunsaturated fatty acids and inflammation. Biochemical Society Transactions 33, 423–427.
24-Glaser R, Robles T, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. (2003). Mild depressive symptoms are associated with amplified and prolonged inflammatory responses following influenza vaccination in older adults.Arch Gen Psychiatry 2003;60:1009 –14.
25-Fritsche, K. (2006). Fatty acids as modulators of the immune response. Annual Reviews of Nutrition, 26, 45-73.
26-Grimble RF (1996) Interaction between nutrients, proinflammatory cytokines and inflammation. Clinical Science 91, 121–130. 53-Haag M. (2003). Essential fatty acids and the brain. Can J Psychiatry 2003;48: 195–203.
27-Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G,(2001). Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745–E751.
28-Smith III, R. S. Chapkin* and D. N. McMurray*,(2004). Dietary 3polyunsaturated fatty acids suppress splenic CD4 +T cell function in interleukin (IL)-10mice, doi:10.1111/j.1365-2249.2004.02685.x
29-Pedersen BK, Anders DT. (2000).Effects of exercise on the lymphocytes and cytokine-. Br J Sports Med 2000;34:246–51.
30-Zhang, JM. An, Cytokines, inflammation and pain, Int. Anesthesiol. Clin. 45 (2007) 27–37.
31-Cannon JG (2000) Inflammatory cytokines in nonpathological states. News Physiol Sci 15:298– 303
32-Kelley D. ( 2001) Modulation of Human Immune and Inflammatory Responses by Dietary Fatty Acids Nutrition;17:669–673
33-Elenkov IJ, Chrousos GP, Wilder RL (2000) Neuroendocrine regulation of IL-12 and TNF-alpha/IL-10 balance. Clinical implications. Ann NY Acad Sci 917:94–105
34-Dunning T. Care of people with diabetes: a manual of nursing practice. Australia: Blackwell publishing; 2003
35-Salmeron J, Hu FB, Manson JE, Stampfer MJ ,ColditzGA, Rimm EB, et al. Dietary fat intake and risk of typ2 ediabetes in women. Am J Clin Nutr 2001;73(6):1019
Clin Experiment Ophthalmol 2006;34(5):464-71 36-Chong EWT, Sinclair AJ, Guymer RH. Facts onfats
37-World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate
hyperglycemia: WHO/IDF Consultation; 2006
38-
39-Mori TA & Beilin LJ (2004) Omega-3 fatty acids and inflammation. Current Atherosclerosis Reports 6, 461–467.
40-Baumann KH, Hessel F, Larass I, Mu¨ller T, Angerer P, Kiefl R & von Schacky C (1999) Dietary omega-3, omega-6, and omega- 9 unsaturated fatty acids and growth factor and cytokine gene expression in unstimulated and stimulated monocytes. A randomized volunteer study. Arteriosclerosis, Thrombosis, and Vascular Biology 19, 59–66.
41-Simopouloos A.P. (2008) Omega 3 Fatty Acids, Exercise, Physical Activity and Athletics Nutrition and Fitness; vol 98 ,pp 23-50
42-DaCosta D, Dritsa M, Ring A, Fitzcharles MA. Mentalhealth status and leisure-time physical activity
contribute to fatigue intensity in patients withspondylarthropathy.Arthritis Rheum 2004 15; 51: 1004
43-Gil A..(2002). Polyunsaturated fatty acids and inflammatory diseases. Biomed Pharmacother 2002; 56: 388–96.
44-Vernon RG, denis RG and sorenses a.signals of adiposity.domest anim endocrinol 21:197-214,2001.
45-J Bloomer R*, Larson D. E, Fisher-Wellman K.S
Galpin A.J and Schilling B.K. Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study, Lipids in Health and Disease 2009, 8:36 doi:10.1186/1476-511X-8-36
46-Nieman D. C, DrPH, FACSM, N-3 polyunsaturated fatty acids do not alter immune and inflammation measures in endurance athletes. Dept HLES, PO Box 32071, Appalachian StateUniversity, Boone,
47-Toft AD, Thorn M, Ostrowski K, Asp S, Moller K, Iversen S, Hermann C, Sondergaard SR & Pedersen BK (2000) N-3 polyunsaturated fatty acids do not affect cytokine response to strenuous exercise. Journal of Applied Physiology 89, 2401–2406.
48-Dinarello CA (2006) Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. American Journal of Clinical Nutrition 83, Suppl., 447S–455S.
49-Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC & Grimble RF (2003) Association of n-3 polyunsaturated fatty acids with stability of
atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477–485.
50--World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate
hyperglycemia: WHO/IDF Consultation; 2006
51-Kahan CR.banting lecture.Insulin, diabetogenes,and the cause of type II diabetes.diabetes 43:1066-1084,1994.
52-Calder PC, Grimble RF.(2002). Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr 2002; 56 (Suppl. 3): S14–9.
53-Mokdad AH ,Serdula MK,dietz WH,bowman BA, Marks JS and Koplan JP.The continuing epidemic of obesity in the United States.JAMA 284:1650-1651.2000.
54-Calder,(2006). N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases, Am. J. Clin. Nutr. 83 (2006) 1505S–1519S.
55-Calder, P.C. (2007). Immunomodulation by omega-3 fatty acids. Prostaglandins, Leukotrienes and Essential Fatty Acids, 77, 327-335.
56-Mokdad AH,Bowman BA ,ford ES ,vinicor F,marks JS and koplan JP .The continuing epidemic of obesity and diabetes in the United States.JAMA 286:1195 -1200,2001.
57- Calder P.C. (2009) Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale J Biochimie xxx 1–5
58-Charo IF & Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circulation Research 95, 858–866.
59-Bogardus C.Insulin resistance in the pathogenesis of NIDDM in pima Indians.diabetes care 16:228-231,1993.
60-De Caterina R, Spiecker M, Solaini G, Basta G, Bosetti F, Libby P, Liao J (1999 ).The inhibition of endothelial activation by unsaturated fatty acids. Lipids 34(Suppl):S191–S194
61-Peters E M ( 2004 ) Postrace upper respiratory tract ‘infections’ in ultramarathoner infection, allergy or inflammation? SPORTS MEDICINE VOL 16 NO.1
62-Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. (1993).Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol1993; 150:353–60.
63-de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. (1991).Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. JExp Med 1991; 174:1209–20.
64-Paula J. Robson-Ansley ,Andrew Blannin Michael Gleeson. (2007). Elevated plasma interleukin-6 levels in trained male triathletes following an acute period of intense interval training. Eur J Appl Physiol ,99:353–360
65-Ernst, E., Saradeth, T., & Achhammer, G. (1991). N-3 fatty acids and acute-phase proteins. European Journal of Clinical Investigation, 21, 77-82.
66-Evans AR, Vasko MR, Nicol GD (1999). The cAMP transduction cascade mediates the PGE2-induced inhibition of potassium currents in rat sensory neurons. J. Physiol 516):163–178
67-Ferrucci, Antonio Cherubini, Stefania Bandinelli, Benedetta Bartali, Annamaria Corsi, Fulvio Lauretani, Antonio Martin, Cristina Andres-Lacueva, Umberto Senin, and Jack M. (2002).Guralnik Relationship of Plasma Polyunsaturated Fatty Acids to Circulating Inflammatory Markers, The Journal of Clinical Endocrinology & Metabolism 91(2):439–446
68-Mohamed-aliV,pinkney JH and coppack SW.adipose tissue as an endocrine organ 35.Int J obes Relat Metab dis ord 22:1145-1158,1998.
69-Botting RM( 2000) Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis 31(Suppl 5):S202–S210
70-Ferroni P,basili S,falco A and davi G.Inflammation,insulin resistance,and obesity.curr Atheroscler Rep 6:424-431,2004.
71-Lau DC,Schillabeer G,Li ZH,wong ki,varzaneh FE and touch SC.paracrine hnteractions in adipose tissue development and growth. In J obes relatmetab disord 20 suppl 3:s16-s25,1996.
72-Akira S, T, kishimoto T,(1993). I nterlukine-6 in biology and medicine . Advances in Immunology 54:1-78
73-Frasure-Smith N, Lesperance F, Julien P. (2004).Major depression is associated with lower omega-3 fatty acid levels in patients with recent acute coronary syndromes. Biol Psychiatry 2004;55:891– 6.
74-Calder PC (2002). Dietary modification of inflammation with lipids. Proc Nutr Soc 61:345–358
75-Naclerio RM, Baroody FM, Togias AG(1991).. The role of leukotrienes in allergic rhinitis: a review. Am Rev Respir Dis 1991;143:S91-5.
76-Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY.(1999).. Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 1999;85: 275–91.
77-Bjorkkjaer T, Brunborg LA, Arslan G, et al. (2004).Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scand J Gastroenterol 2004; 39: 1088–94.
78-Anne Marie W. Petersen and Bente Klarlund Pedersen,(2004).The anti-inflammatory effect of exercise. J Appl Physiol 98: 1154–1162, 2005; doi:10.1152/japplphysiol. 00164.
79-Herrero C, Hu X, Li WP et al(2003). Anti-inflammatory properties of pro-inflammatory interferon-gamma. J Immunol 2003; 171:5034– 41.
80-Pretolani M. Interleukin-10,(1999). an anti-inflammatory cytokine with therapeutic potential. Clin Exp Allergy29: 1164–1171.
81-Prasad K, ChaudharyAK, Kalra J (1991) Oxygen-derived free radicals producing activity and survival of activated polymorphonuclear leukocytes. Mol Cell Biochem 103:51–62
82-Irvine RF 1982 How is the level of free arachidonic acid controlled in mammalian cells? Biochem J 204:3–16
83-Mackinnon, L. T.(2000)a. Chronic exercise training effects on immune function. Med Sci Sports Exerc. 32:S369-376, 2000.
84-Miles, E. Allen, P.C. Calder, (2002).In vitro effects of eicosanoids derived from different 20-carbon Fatty acids on production of monocyte-derived cytokines in human whole blood cultures, Cytokine 20 (2002) 215–223.
85-Pedersen BK, Ostrowski K, Rohde T, and Bruunsgaard H.(1998). The cytokine response to strenuous exercise. Can J Physiol Pharmacol 76: 505–511, 1998
86-Jolly CA, Jiang YH, Chapkin RS, and McMurray DN.(1997). Dietary (n-3) polyunsaturated fatty acids suppress murine lymphoproliferation, interleukin-2 secretion, and the formation of diacylglycerol and ceramide. J Nutr 127: 37–43, 1997.
87- Kamimura D, Ishihara K, Hirano T,(2003). IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149: 1–38.
88-Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W.(1993). IL-10: a novel cytotoxic T cell differentiation factor. Cell 1993; 75:263–74.
89-Ostrowski K, Rohde T, Zacho M, Asp S, and Pedersen BK(1998). Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol (Lond) 508: 949–953, 1998
90-Hersh EV, MoorePA, Ross GL (2000). Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther 22:500–548
91-James MJ, Gibson RA & Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. American Journal of Clinical Nutrition 71, Suppl., 343S–348S.
92-Toft AD, Thorn M, Ostrowski K, Asp S, Moller K, Iversen S, Hermann C, Sondergaard SR & Pedersen BK (2000) N-3 polyunsaturated fatty acids do not affect cytokine response to strenuous exercise. Journal of Applied Physiology 89, 2401–2406.
93-Von Schacky C & Harris WS (2007) Beneficial cardiovascular effects of omega-3 fatty acids. Cardiovascular Research 72, 310–315.
94-von Schacky, n-3 PUFA in CVD(2007). influence of cytokine polymorphism, Proceedings of the Nutrition Society (2007), 66, 166–170
95-Holm T, Berge RK, Anderassen AK, Ueland T, Kjekshus J, Simonsen S, Froland S, Gullestad L & Aukrust P (2001) Omega-3 fatty acids enhance tumor necrosis factor-alpha levels in heart transplant recipients. Transplantation 72, 706–711.
96-Arrington JL, McMurray DN, Switzer KC, Fan YY, Chapkin RS.(2001). Docosahexaenoic acid suppresses function of the CD28 costimulatory membrane receptor in primary murine and Jurkat T cells. J Nutr 2001; 131:1147–53
97-Zhao, S. Joshi-Barve, S. Barve, L.H. Chen, (2004).Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation, J. Am. Coll. Nutr. 23 (2004) 71–78
98-Berg DJ, Kuhn R, Rajewsky K et al.(1995). Interleukin-10-deficient mice develop chronic enterocolitis. J Clin Invest 1995; 96:2339–47.
99-Blotta, M. H., R. H. DeKruyff, and D. T. Umetsu. (1997). Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol. 158:5589-5595, 1997.
100-Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC et al. (2006) AHA/ACC Guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 113, 2363–2372.
101-Trebble T, Arden NK, Stroud MA, Wootton SA, Burdge GC, Miles EA, Ballinger AB, Thompson RL & Calder PC (2003) Inhibition of tumour necrosis factor-a and interleukin 6 production by mononuclear cells following dietary fishoil supplementation in healthy men and response to antioxidant co-supplementation. British Journal of Nutrition 90, 405–412.
102-Raines EW (2004) PDGF and cardiovascular disease. Cytokine and Growth Factor Reviews 15, 237–254.
103-Richard, D., Kefi, K., Barbe, U., Bausero, P., & Visioli, F. (2008). Polyunsaturated fatty acids as antioxidants. Pharmacological Research, 57, 451-455.
104-Vandenburgh HH, Hatfaludy S, Sohar I, Shansky J (1990) Stretch-induced prostaglandins and protein turnover in cultured skeletal muscle. Am J Physiol 259:C232–C240
105-Chiu, M.J. Fu, A. Chu, S. Helton,(2000). Fish oil modulates macrophage P44/42 mitogen-activated protein kinase activity induced by lipopolysaccharide, J. Parent. Ent. Nutr. 24 (2000) 159–163.
106-Calder P.C. ( 2001) N-3 polyunsaturated fatty acids, inflammation and immunity:
pouring oil on troubled waters or another fishy tale? Nutrition Research 21 : 309–341
107-MORITZ1 Elisabeth WAZLAWIK1 Jaqueline MINATTI2 Rafaella Cristina DIMBARRE DE MIRANDA2(2008).Omega-3 fatty acids interference on the blood lipids of rats subjected to swimming exercise, Rev. Nutr., Campinas, 21(6):659-669, nov./dez.,
108-Berguer, R., N. Bravo, M. Bowyer, C. Egan, T. Knolmayer, and D. Ferrick. (1999).Major surgery suppresses maximal production of helper T-cell type 1 cytokines without potentiating the release of helper T-cell type 2 cytokines. Arch Surg. 134:540-544, 1999.
109-Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J( 2002). Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346:1113–1118
110-Bordoni A, Astolfi A, Morandi L, Pession A, Danesi F, Di Nunzio M, et al.(2007). N-3 PUFAs modulate global gene expression profile in cultured rat cardiomyocytes. Implications in cardiac hypertrophy and heart failure. FEBS Lett 2007;581:923e9.
111-Kaminski WE, Jendraschak E, Kiefl R & von Schacky C (1993) Dietary _w-3 fatty acids lower levels of PDGF mRNA in human mononuclear cells. Blood 81, 1871–1879.
112-Serhan, N. Chiang, T.E. van Dyke,(2008). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators, Nat. Rev. Immunol. 8 (2008) 349–361.
113-Serhan N, Chiang TE, van Dyke.(2008). Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 8(5) , 349–361.
114-Mukherjee, V.L. Marcheselli, C.N. Serhan, N.G. Bazan, Neuroprotectin D1: (2004).a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress, Proc. Natl. Acad. Sci. USA 101 (2004) 8491–8496.
115-Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC & Rimm EB (2003) Habitual dietary intake of n-3 and n-3 fatty acids in relation to inflammatory markers among US men and women. Circulation 108, 155–160.
116-Tilley, T.M. Coffman, B.H. Koller, (2001).Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes, J. Clin. Invest. 108 (2001) 15–23
117-Rihoux JP, Masliah J, Bereziat G, Konig W. G (1997).proteins as biological targets
for anti-allergic drugs? Int Arch Allergy Immunol 1997;113:339-41.
118-Soberman RJ, Harper TW, Betteridge D, Lewis RA, Austen KF.(1985). Characterization
and separation of the arachidonic acid 5-lipoxygenase and linoleic acid -6 lipoxygenase (arachidonic acid 15-lipoxygenase) of human polymorphonuclear leukocytes. J Biol Chem 1985;260:4508-15.
119-Vachier, P. Chanez, C. Bonnans, et al.(2002)., Endogenous anti-inflammatory mediators from arachidonate in human neutrophils, Biochem. Biophys. Res. Commun. 290 (2002) 219–224.
120-Serhan, A. Jain, S. Marleau, et al., (2003).Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators, J. Immunol. 171 (2003) 6856–6865.
121-Palmer RM (1990 ).Prostaglandins and the control of muscle protein synthesis and degradation. Prostaglandins Leukotrienes Essent Fatty Acids 39:95–104
122-Raja SN, Meyer RA, Campbell JN (1988 )Peripheral mechanisms of somatic pain. Anesthesiology 68:571–590
123-Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, Cox B, Zhang H & Schoenfeld D(2005). for the Fatty Acid Antiarrhythmia Trial Investigators (2005) Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 112, 2762–2768209. 209.
124-Mori TA & Beilin LJ (2004) Omega-3 fatty acids and inflammation. Current Atherosclerosis Reports 6, 461–467.
125-NIELSEN*, L. G. M. JØRGENSEN*, J. N. NIELSEN*, M. EIVINDSON_, H. GRØNBÆK_, I. VIND§, D. M. HOUGAARD–, K. SKOGSTRAND–,**, S. JENSEN__, P. MUNKHOLM__, I. BRANDSLUND*,§§ & H. HEY§§, (2005).Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn’s disease compared with omega-6 fatty acids, Aliment Pharmacol Ther 2005; 22: 1121–1128.
126-Priscila M.M. Andradea, Beatriz G. Ribeiroa, Marcelo T. Bozzab,Luiz Fernando B. Costa Rosac, Maria G. Tavares do Carmoa,(2007). Effects of the fish-oil supplementation on the immune andinflammatory responses in elite swimmers, Prostaglandins, Leukotrienes and Essential Fatty Acids 77 (2007) 139–145
127-Rees, E.A. Miles, T. Banerjee, et al.,(2006). Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men, Am. J. Clin. Nutr. 83 (2006) 331–342
128-Fritsche KL, Alexander DW, Cassity NA, and Huang SC.(1993). Maternally-supplied fish oil alters piglet immune cell fatty acid profile and eicosanoid production. Lipids 28: 677–682, 1993.
129-Von Schacky, R. Kiefl, E. Jendraschak, W.E. Kaminski,.(1993) N-3 fatty acids and cysteinyl-leukotriene formation in humans in vitro, ex vivo and in vivo, J. Lab. Clin. Med. 121 (1993) 302–309.
130-Lee, J.M. Mencia-Huerta, C. Shih, et al.,(1984). Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including eukotriene-B5 and the double lipoxygenase product, J. Biol. Chem. 258 (1984) 2383–2389.
131-Kelley, P.C. Taylor, G.J. Nelson, et al., (1999). Docosahexaenoic acid ingestion inhibits natural killer cell activity and production of inflammatory mediators in young healthy men, Lipids 34 (1999) 317–324.
132-Healy, F.A. Wallace, E.A. Miles, P.C. Calder, P.(2000). Newsholme, The effect of low to moderate amounts of dietary fish oil on neutrophil lipid composition and function, Lipids 35 (2000) 763–768.
133-Robinson, M. Urakaze, R. Huang, et al., (1996).Dietary marine lipids suppress continuous expression of interleukin-1b gene expression, Lipids 31 (1996) S23–S31.
134-Kumar, Y. Takada, A.M. Boriek, B.B. Aggarwal, (2004). Nuclear factor-kappaB: its role in health and disease, J. Mol. Med. 82 (2004) 434–448.
135-Perkins, (2007).ntegrating cell-signalling pathways with NF-kappaB and IKK function, Nat. Rev. Mol. Cell Biol. 8 (2007) 49–62.
136-sZhao S, Barve J, Barve S, Chen LH.(2004). Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr. 23(1): 71–78.
137-Nicole M. J. Schwerbrock, Erik A. Karlsson, Qing Shi, Patricia A. Sheridan, and Melinda A. Beck3*(2009) Fish Oil-Fed Mice Have Impaired Resistance to Influenza Infection The Journal of Nutrition Nutritional Immunology
138-Mayer Konstantin, Stephanie Gokorsch, Christine Fegbeutel, Katja Hattar, Simone Rosseau, Dieter Walmrath, Werner Seeger, and Friedrich Grimminger,(2003). Parenteral Nutrition with Fish Oil Modulates Cytokine Response in Patients with Sepsis Am J Respir Crit Care Med Vol 167. pp 1321–1328, 2003
139-Northoff H and Berg A. (1991).Immunologic mediators as parameters of the reaction to strenuous exercise. Int J Sports Med 12 Suppl 1:S9–15: S9–15, 1991
140-Nieman, D.C. (2007). Marathon training and immune function. Sports Medicine, 37, 412-415.
141-Turner M, Chantry D, Katsikis P, Berger A, Brennan FM, and Feldmann M.(1991). Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-beta. Eur J Immunol 21: 1635–1639, 1991.
142-Andrade P. et al . ( 2007) Effects of the fish-oil supplementation on the immune and inflammatory responses in elite swimmers Prostaglandins, Leukotrienes and Essential Fatty Acids 77 : 139–14
143-Mancardi*, Francesca Tullio, Antonio Crisafulli, Raffaella Rastaldo, Anna Folino, Claudia Penna, Pasquale Pagliaro, (2009).Omega 3 has a beneficial effect on ischemia/reperfusion injury, but cannot reverse the effect of stressful forced exercise. Nutrition, Metabolism & Cardiovascular Diseases (2009) 19, 20e26
144-Brooks GA, Fahey TD, White TP.(1995). Exercise physiology: human bioenergetics and its applications. Mountain View, CA: Mayfield Publishing; 1995.
145-Calder, P.C., (2008). Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Molecular Nutrition and Food Research, 52, 885-897.
146-Simopoulos, A.P. (2007). Omega-3 fatty acids and athletics. Current Sports Medicine Reports6, 230-236.
147-Raastad, T., Høstmark, A.T., & Strømme, S.B. (1997). Omega-3 fatty acid supplementation
148- Robson P (2003) Elucidating the unexplained underperformance syndrome in endurance athletes: the interleukin-6 hypothesis. Sports Med 33:771–781
149-Walser, B., & Stebbins, C.L. (2008). Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise. European Journal of Applied Physiology, 104,455-461.
150-Ninio, D.M., Hill, A.M., Howe, P.R., Buckley, J.D., & Saint, D.A. (2008). Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults. British Journal of Nutrition, 100, 1097-1103.
151-Hamdy O, L. J.Goodyear,E.S.Horton. Dite and exercise in type2 diabetes mellitus.Endocrinol Metabol Clin North America.30:883-907.2001
152-Ross R,J,A.Freeman,L janssen.Exercise alone is an effective strategy for reduding obesity and related comorbidities.exerc Sport Sci Rev.28.65-70.2000
153-RossE,I.Janssen.Physiccal activity,total and reginal obesity :dose-reponse considerations.Med Sci sport Excerc.:23:S521-S527.2001.
154-Houmard JA, M.S.Hickey,G.L.Tyndall,K.E.Gavigan, G.Dohm, L. Dohm.Seven days of exercise increase GLUT-4 protein content in humam skeletalmuscal.J Appl Physol..79:1936-1938.1995
155-Helmrich T, D.R.Ragland, R.W.Leung,R.S. Paffenbarger.physical activity and red occurance of non-insulin dependent diabetes mellitus.N Engl J Med..325:147-152.1991
156-Tumilehto J, J. Lindstrom.Prevention of type diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.N Engl J Med..344:1343-1350.2001
157-Hoummard JA, P.S.Maclean.Effect of short-term exercise trianing on leptin and insulin action.Metabolism..49:858-861.2000
158-Perseghin B, T.B. Price,K.F.Petersen.Increased glucose transport ohosphoryation and muscle glycogen synthesis after exercise training in insulin resistant subjects.N Engl J Med..335:P1357-1362.1996
159-Vranic M. M.Berger.Excrcise and diabetes mellitus.diabetes..28:147-167.1979
160-Wing RR, L.H.Epstein.Exercise in a behavioral weight control program for obese patients with type2 diabetes. Diabeteologia..31:902-909.1988
161-kemmer FW,M,Berger.Exercise and diabetesmellitus:Physical activity as a part of daily life and its role in the treatment of diabetic patients.Int J Sports Med..4:77-88.1983
162-Wahren J, P.Felig.Physical exercise and fuel homeostasis in diabetes mellitus.diabetologia..14:213-222.1978
163-Wallberg-Henrickson H. Glucose transport into skeletal muscle: Influence of contractile activity, hnsulin,catecholamines and diabetes mellhtus.Acta Phys Scand..131:S661.1987
164-Ruderman NB,K.Johansen.The effect of physical training on glucose tolerance and plasma lipids in maturity-onset diabetes.diabetes..28:89-92.1979
165-Wing RR, R.Koeske, W.Goodling.Long-term effects of modest weight loss in type 2 diabetic patients.Arch Intern Med..147:1749-1753.1987
166-ChipkinSR, S.A.Kihan,L,Chasan-Taber.Exercise and diabetes.Cardiology Clinics..19:489-505.2001
167-Koivisto VA, R.A.Defronzo.Exercise in the treatment of Type 2 diabetes.Acta Endocr..262:107-11.1984
168-Schneider SH, L.F. Amurosa.Abnormal glucoregulation during exercise in type 2 diabetes. Metabolism..36:1161-1166.1987
169-Mincak HL, M. Vranic.Glucoregulatory and metabolic response to bexercise in obese non- hnsulin-dependent diadetes. AmJ Physiol..240:E458-E464.1981
170-HubingerA, A.Franzen,F.A.Gries.Hormonal and metabolic response to physical exercise in hyperinsulinaemic and non-hyperinsulinaemic type2 diabetics.Diabetes Res..4:57-61.1987
171-Schneider SH,N.B.Ruderman.Exercise and type 2 diabetes.diabetes Care..13:785-789.1990
172-Paternostro-Bayles M, R.R.Wing, R.G.Robertson.Effectof lifestyle activity of varying duration on glycemic control in type 2 diabetic women.Diabetes Care..12:34-37.1989
173-BraunB, M.B. Zimmermann,N.Kretchmer. Effects of exerchse intensity on insulin sensitivity in women with non-insulin-dependent diabetes mellitus.J Appl..78:300-306.1995
174-LarsenJ,F.Dela,S.Madsbad,H.Galbo.The effect of intense exercise on postprandial glucose homeostasis in type 2 diabetic patients.Diabetologia..42:1282-1292.1999
175-Zhang YX, W.J.Cliff.Coronary C-reactive protein distribution:its relation to development of atherosclerosis.Atherosclerosis..145:375-379.1999
176-KennedyJ, M.F Hirshman.Acute exercise induces GLUT-4 translocation in skeletal muscle of normal human subjects with type 2 diabetes.Diabetes.48:1192-1197.1999
177-Henrickcsen EJ.Exercise effects of muscle insulin signaling and dction.Invited Review:efects of acute exercise and exercise training on hnsulin rewsistance.J Appl Physiol..93:788-796.2002
178-MusiN, N.Fugii. M.F.Hirshman. AMP-activated protien kinase(AMPK) is activated in muscle of subjects with type 2 diabetes during exercise.Diabetes..50:921-927.2001
179-BursteinR,Y.Epstein, Y.Shapiro.Effect of an acute bout of exercise on glucose dhsposal hn human obesity.J appl Physiol..69:299-304.1990
180-Devlin JT,M.Hirschman,E.D Horton.Enhanced peripheral and splachnic insulin sensitivitiy in type 2 diabetic men after asingle bout of exercise.Diabetes..36:434-439.1987
181-Anand, R.G., Alkadri, M., Lavie, C.J. and Milani, R.V., 2008. The role of fish oil in
arrhythmia prevention. J Cardiopulm
Rehabil Prev, 28(2), pp.92-98.
182-HeathGW,J.R.Gavin.Effects of exercise and lack of exercise on glucose tolerance and hnsulin sensitivity.J Appl Physiol..55:512-517.1983
183- Fluckey JD, M.S. Hickey, H.K. Brambrink. Effects of resistance exercise on glucose tolerance hn normal and glucose intolerant subjects.J Appl Physiol..77:1087-1092.1994
184-Pedersen B.K..(2007) ,IL-6 signalling in exercise and disease, A Focus Topic at Life Sciences held at SECC Glasgow, U.K., 9–12 July .
185-Le BlancJ,A. Nadeau, D. Richard.Studies on the sparing effect of exercise on insulin requirements in human subjects.Metabolism..30:1119-1124.1981
186-Pedersen BK, Hoffman-Goetz L,(2000). Exercise and the immune system:regulation, integration and adaption. Physiol Rev 80: 1055–1081.
187-Rohit Gokhale a, S. Chandrashekara b,*, K.C. Vasanthakumar.(2007). Cytokine response to strenuous exercise in athletesand non-athletes—an adaptive response. Cytokine 40 (2007) 123–127
188-Petersen AM, Pedersen BK. (2006).The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006;57(Suppl 10):43–51.
189-Seder, R. A. (1994). Acquisition of lymphokine-producing phenotype by CD4+ T cells. J Allergy Clin Immunol. 94:1195-1202, 1994.
190- Steensberg A, Febbraio MA, Osada T, Schjerling P, van Hall G, Saltin B, Pedersen BK.(2001). Interleukin-6 production in contracting human skeletal muscle is influenced by pre-exercise muscle glycogen content. J Physiol 537: 633–639.
191-Steensberg, A., A. D. Toft, H. Bruunsgaard, M. Sandmand, J.(2001). Halkjaer-Kristensen, and B. K. Pedersen. Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol. 91:1708-1712, 2001.
192-Graeme I. Lancaster1, Shona L. Halson1,3, Qamar Khan2, Pam Drysdale2, Fiona Wallace4, Asker E. Jeukendrup1, Mark T. Drayson2 and Michael Gleeson5,(2000). Effects of acute exhaustive exercise and chronic exercise training on type 1 and type 2 T lymphocytes,RMITUniversity, Bundoora 3083, VIC Australia
193-Budgett R, Newsholme E, Lehmann M, Sharp C, Jones D, Peto T, Collins D, Nerurkar R, White P (2000) Redefining the overtraining syndrome as the unexplained underperformance syndrome. Br J Sports Med 34:67–68
Wahl SM, ChenW(2003 ).TGF_: how tolerant can it be? Immunol Res 28:167–179-194
195-Mickleborough, R.L. Murray, A.A. Ionescu, M.R. Lindley, (2003).Fish oil supplementation reduces severity of exercise-induced bronchocostriction in elite atletes, Am. J. Respir. Crit. Care 168,1181–1189.
196- Sijben, J.W., & Calder, P.C. (2007). Differential immunomodulation with long-chain n-3PUFA in health and chronic disease. Proceedings of the Nutritional Society, 66, 237-259
197-Yusof, H.M., Miles, E.A., & Calder, P. (2008). Influence of very long-chain n-3 fatty acids on plasma markers of inflammation in middle-aged men. Prostaglandins, Leukotrienes and Essential Fatty Acids, 78, 219-228.
198 - Saremi A, Gheraati MR. [The effect of resistance training on serum myostatin level and insulin resistance in obese/overweight men]. HARAKAT.
2010; 4:93-108
199-Mathews DR , Hosker JP, Rudenski As. Homeostasis model assessment : insulin
resistance and B – cell function from fasting plasma glucose insulin concentrations in man.
Diabetologia 1985; 28: 412–419.
200-Anand, R.G., Alkadri, M., Lavie, C.J. and Milani, R.V., 2008. The role of fish oil in
arrhythmia prevention. J Cardiopulm Rehabil Prev, 28(2), pp.92-98.
201-Endres, S., Ghorbani, R., Kelley, V.E Georgilis, K., Lonnemann, G., van der
Meer, J.W., Cannon, J.G., Rogers, T.S., Klempner, M.S. and Weber, P.C., 1989.
The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the
synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med, 320(5), pp.265-271.
202-Ferrucci, L., Cherubini, A., Bandinelli, S., Bartali, B., Corsi, A., Lauretani, F.,
Martin, A., Andres-Lacueva, C., Senin, U. and Guralnik, J.M., 2006. Relationship of
plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin
Endocrinol Metab, 91(2), pp.439-446
203-Chabane Sari, D., Abuharfeil, N., Hudaib, M. and Aburjai, T., 2006.
Effect of n-3 and n-6 polyunsaturated fatty acids on lymphocyte proliferation,
interleukin production and phospholipid fatty acids composition in type 2 diabetic
and healthy subjects in Jordan people. Prostaglandins Leukot Essent Fatty
Acids, 74(6), pp.347-356.
204-Weber, P.C. and Leaf, A., 1991. Cardiovascular effects of omega 3 fatty acids. Atherosclerosis risk factor modification by omega 3 fatty acids. World Rev Nutr Diet, 66, pp.218-232.
205-Magee, P., Pearson, S. and Allen, J., 2008. The omega-3 fatty acid, eicosapentaenoic
acid (EPA), prevents the damaging effects of tumour necrosis factor (TNF)-alpha
during murine skeletal muscle cell differentiation. Lipids Health Dis, 7, p.24.
206-Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ.(2003). NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNFalpha transcription. Am J Physiol Lung Cell Mol Physiol. 284(1): L84–L89.
207-Jellema, A., Plat, J. and Mensink, R.P., 2004. Weight reduction, but not a
moderate intake of fish oil, lowers concentrations of inflammatory markers
and PAI-1 antigen in obese men during the fasting and postprandial state. Eur J
Clin Invest, 34(11), pp.766-773.
208-Klein-Platat, C., Drai, J., Oujaa, M., Schlienger, J.L. and Simon, C., 2005. Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr, 82(6), pp.1178-1184.
209-Schubert, R., Kitz, R., Beermann, C., Rose, M.A., Baer, P.C., Zielen, S. and Boehles, H.,
2007. Influence of low-dose polyunsaturated fatty acids supplementation on the
inflammatory response of healthy adults. Nutrition, 23(10), pp.724-730.
210-Serhan, (2005).Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotrectins, Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 115–121.
211-Ross R (1999) Atherosclerosis – an inflammatory disease. New England Journal of Medicine 340, 115–126.
212-Shreedhar V. (1998) A Cytokine Cascade Including Prostaglandin E2, IL-4, and IL-10 IsResponsible for UV-Induced Systemic Immune Suppression1 The Journal of Immunology , 1998, 160: 3783–3789.
213-Robson-Ansley et al. ( 2006) Elevated plasma interleukin-6 levels in trained male
Triathletes following an acute period of intense interval training Eur J Appl Physiol
214-Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST.(2003). Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A 2003; 100: 1751–6.